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Introduction: Dasatinib is a dual SRC/ABL tyrosine kinase inhibitor used to treat chronic 
myeloid leukemia (CML) that is known to have unique immunomodulatory effects. In 
particular, dasatinib intake typically causes lymphocytosis, which has been linked to 
better clinical response. Since the underlying mechanisms are unknown and SRC family 
kinases are involved in many cell motility processes, we hypothesized that the movement 
and migration of lymphocytes is modulated by dasatinib.
Patients, Materials and Methods: Peripheral blood samples from CML patients treated 
with second-line dasatinib were collected before and 2 h after the first dasatinib intake, 
and follow-up samples from the same patients 3 and 6 months after the start of therapy. 
The migratory capacity and phenotype of lymphocytes and differential blood counts 
before and after drug intake were compared for all study time-points.
Results: We report here for the first time that dasatinib intake is associated with inhibition 
of peripheral blood T-cell migration toward the homeostatic chemokines CCL19 and 
CCL21, which control the trafficking toward secondary lymphoid organs, mainly the 
lymph nodes. Accordingly, the proportion of lymphocytes in blood expressing CCR7, the 
chemokine receptor for both CCL19 and CCL21, decreased after the intake including 
Frontiers in Pharmacology | www.frontiersin.org November 2019 | Volume 10 | Article 1340
ORIgINAL REsEARCh
doi: 10.3389/fphar.2019.01340
published: 25 November 2019
Dasatinib Redistributes Naïve and Memory LymphocytesColom-Fernández et al.
2
INTRODUCTION
Dasatinib is a second generation multitargeted tyrosine kinase 
inhibitor (TKI) directed against BCR-ABL, which is approved for the 
treatment of Philadelphia chromosome positive (Ph+) leukemias, 
including newly diagnosed chronic myeloid leukemia (CML) in 
the chronic phase (Talpaz et al., 2006; Jabbour and Lipton, 2013). In 
addition to the BCR-ABL fusion protein, dasatinib inhibits with high 
potency several receptor tyrosine kinases (RTK) such as c-KIT or 
platelet-derived growth factor receptors (PDGFR) as well as a broad 
range of cytoplasmic kinases including TEC, SYK, and SRC family 
kinases (SFK) (Bantscheff et al., 2007; Rix et al., 2007; Steegmann et 
al., 2012). SFK are involved in mediating signal transduction from 
cell surface receptors and regulate fundamental cellular processes 
including migration, adhesion, invasion, angiogenesis, proliferation, 
and differentiation (Parsons and Parsons, 2004). Therefore, SFK play 
a major role in the development, growth, progression, and metastasis 
of a wide variety of human cancers, and their inhibition by dasatinib 
can suppress tumor growth and metastatic dissemination of several 
human cancer cell lines (Montero et al., 2011). Finally, several kinase 
targets of dasatinib are known to be important in the immune 
system function. For example, ZAP-70, LCK, FYN, and ITK are 
essential in T-cell signaling, while LYN, SYK, and BTK play key roles 
in B-cell receptor signalosome function (Donato et al., 2003; Pene-
Dumitrescu and Smithgall, 2010).
The physiological recirculation of lymphocytes between 
peripheral blood (PB), bone marrow, secondary lymphoid organs 
(SLO) and other tissues is regulated by a variety of chemokines 
and their corresponding receptors, which participate in the rolling 
and firm adhesion phases of the lymphocyte extravasation cascade 
through the endothelium (Viola et al., 2008; Alon and Shulman, 
2011). One of the most important chemokine/receptor pairs is 
the CCR7 receptor and its ligands, the homeostatic chemokines 
CCL19 and CCL21, which mediate the main trafficking pathway 
of T-cells from blood to SLO (Moschovakis and Förster, 2012). 
Another important pathway in lymphocyte homing to SLO and 
bone marrow is the CXCR4/CXCL12 axis (Griffith et al., 2014).
Because of its wide inhibition profile, dasatinib inhibits kinases 
also in healthy normal cells, such as lymphocytes, a mechanism 
that probably underlies many of the immunomodulatory effects 
attributed to this drug (Steegmann et al., 2016). Among them, 
in 2009, Mustjoki et al. reported persistent clonal expansion of 
cytotoxic T-cells or NK-cells in a distinct group of Ph+ patients 
receiving dasatinib therapy (Mustjoki et al., 2009; Kreutzman et al., 
2010; Nagata et al., 2010; Kreutzman et al., 2011; Powers et al., 2011). 
Later, the same group showed that dasatinib intake induces a rapid, 
dose-dependent, and substantial mobilization of lymphocytes in 
blood peaking 1–2 h after oral intake (Mustjoki et al., 2013). More 
recently, Paydas and Schiffer et al. investigated, in a large group 
of patients, the actual incidence of lymphocytosis (Paydas, 2014; 
Schiffer et al., 2016). They confirmed that lymphocytosis is not 
observed with other TKI and verified its association with higher 
response rates and significantly longer response duration. In 
particular, patients with imatinib-intolerant or imatinib-resistant 
chronic phase who developed lymphocytosis after treatment 
with dasatinib had better progression-free and overall survival, 
suggesting a quite specific immunomodulatory effect of dasatinib.
However, the reasons for the benefit of dasatinib-induced 
lymphocytosis and its underlying mechanisms are not clear and 
deserve further research. In this study, we hypothesized that 
dasatinib may induce lymphocyte mobilization from lymphoid 
organs or peripheral tissues, it may inhibit their physiological 
recirculation from the bloodstream to these organs and tissues, 
or both mechanisms. To our knowledge, there are no reports 
studying the effects of dasatinib intake on lymphocyte migration 
ex vivo. Therefore, our aim was to study whether the intake of 
dasatinib changes the migratory pattern of the lymphocytes of 
the patients as a possible cause of lymphocytosis, to gain insight 
into the immunomodulatory effect of this TKI.
PATIENTs AND METhODs
study Patients and samples
A total of 17 CML patients treated with dasatinib were included 
in this study. The patients were enrolled in the DASAPOST phase 
II study (NCT01802450), designed to evaluate the efficacy and 
safety of treatment change to dasatinib in patients previously 
treated with first line imatinib who had shown late suboptimal 
response (patients with complete cytogenetic response (CCyR) 
without major molecular response (MMR) after at least 18 
months of treatment) according to the ELN 09 recommendations. 
DASAPOST study was approved by the Clinical Research Ethics 
Committee of Hospital Universitari Germans Trias i Pujol 
(Badalona, Barcelona, Spain). Patients were treated with dasatinib 
(Sprycel) 100 mg QD administered orally as continuous daily 
dosage. A group of healthy donors and a different cohort of CML 
patients were also included in some experiments. This last cohort 
included CML patients treated for more than three months with 
first line or second line dasatinib (100 mg QD) administered 
both naïve CD45RA+ and central memory CD45RO+ T-cells. Similarly, naïve B-cells 
diminished with dasatinib. Finally, such changes in the migratory patterns did not occur 
in those patients whose lymphocyte counts remained unchanged after taking the drug.
Discussion: We, therefore, conclude that lymphocytosis induced by dasatinib reflects 
a pronounced redistribution of naïve and memory populations of all lymphocyte subsets 
including CD4+ and CD8+ T-cells and B-cells.
Keywords: Dasatinib, lymphocytosis, CCR7, migration, chronic myeloid leukemia
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orally as continuous daily dosage. The analysis of this second 
cohort was approved by the Clinical Research Ethics Committee 
of Hospital Universitario La Princesa (Madrid, Spain) (Reference 
number PI-561). The study was conducted in accordance with 
the Declaration of the Helsinki principles. Written informed 
consent was obtained from each patient and healthy controls 
prior to sample collection. All measurements of BCR-ABL/ABL 
levels (international scale, IS) were centralized in a sole EUTOS 
(European Treatment and Outcome Study for CML) laboratory.
PB samples were obtained the day the patients switched to 
dasatinib for DASAPOST patients, and at any time point after 
three months of dasatinib treatment for patients in the other cohort 
described above. For each patient, two samples were collected: one 
before the dasatinib dose (preintake sample) and the other one 2 h 
after drug intake (postintake sample). Only patients having paired 
preintake and postintake samples were included in the analysis.
Dasatinib used for in vitro assays was purchased from 
Selleckchem, Houston, TX, USA (HPLC purity 99.8%).
Immunophenotyping
Immunophenotyping of preintake and postintake samples was 
performed on fresh whole blood within 24 h after extraction using 
the following monoclonal antibodies (mAbs): CD45-V500 (BD; 
clone HI30), CD3-PerCP (BD; clone SK7), CD8-APC-H7 (BD; 
clone SK1), CD16-Pacific Blue (BD; clone 3G8), CXCR4 (CD184)-
PECy7 (BD; clone 12G5), CD56-Brilliant Violet 421 (Biolegend; 
clone HCD56), CCR7 (CD197)-PE (RyD; clone 150503), CD27-PE 
(BD; clone M-T271), CD45RA-FITC (BD; clone HI100), CD45RO-
PECy7 (BD; clone UCHL1). Monoclonal isotype controls (IC) 
were used to define basal levels of immunofluorescence. Whole 
blood was incubated with the antibodies for 15 min followed by 
standard lysis and washing steps. A minimum of 100,000 events 
were acquired with FACSCanto™ II flow cytometer and analyzed 
using FACSDiva software (both from BD Biosciences, USA). First, 
lymphocytes were identified as CD45+ and then T, B and NK 
cells were identified as CD3+, CD19+ and CD3-CD16+CD56+ 
lymphocytes, respectively. CXCR4 and CCR7 expression was 
evaluated on CD8+ T-cells (CD3+CD8+) and CD4+ T-cells 
(CD3+CD8-). Finally, naïve (TN), central memory (TCM), effector 
memory (TEM), and CD45RA+ effector memory (TEMRA) T-cells 
were defined as CCR7+CD45RA+, CCR7+CD45RO+, CCR7-
CD45RO+, and CCR7-CD45RA+ T cells, respectively, following 
the strategy showed in Figure 1. CD27 was used to identify naïve 
CD27- B-cells and memory CD27+ B-cells.
Migration Assay
PB mononuclear cells (PBMCs) from preintake and postintake 
samples were separated by Ficoll gradient centrifugation and 
serum starved in RPMI+0.1% BSA for 30 min. The chemokines 
CCL19+CCL21 (1 μg/ml) and CXCL12 (0.5 μg/ml) (all 
PeproTech, Rocky Hills, NJ, USA; SDS-PAGE and HPLC purity 
≥ 98%) were added to 24-well plates in a final volume of 600 μl. 
Polycarbonate filter (5-μm pore size, 6.5-mm membrane, 10-mm 
thickness, Costar, Cambridge, MA, USA) transwell-inserts were 
put on top of the wells and starved cells (5x105 cells in 100 μl) 
were added into the upper chamber of the transwell and were 
allowed to migrate for 3h at 37°C in 5% CO2 atmosphere.
The assay included two control wells: input cells (maximum 
of cells = 500,000) and basal migration without chemoattractant 
in the lower chamber. After 3 h, the migrated cells in the lower 
chamber were collected into tubes and antibodies against CD45, 
CD3, CD4, CD8, and CD56 were added to each tube. Events 
were acquired for 210 s by flow cytometry (FACSCanto™ II) and 
data were analyzed using FACSDiva software. Gates were set as 
described in the Immunophenotyping section.
Two parameters were used to evaluate lymphocyte migratory 
capacity: the percentage of migrated cell and the migratory 
index. The percentage of migrated cells was calculated as the 
ratio between the number of cells migrated in response to CCL19 
and CCL21, or CXCL12 and the number of cells present in the 
input well. The migratory index was defined as the ratio between 
the number of cells migrated in response to each chemokine and 
the number of cells migrated into the basal well.
Similarly, in vitro effects of dasatinib were analyzed with PBMC 
from healthy donors, which were pretreated with dasatinib (100 
nM) for 1 h and allowed to migrate for 3 h in the presence of the 
inhibitor.
statistical Analyses
Descriptive analysis of the sample: variables were described by their 
measures of central tendency (mean) and dispersion (standard 
deviation (SD)) or standard error of the mean (SEM). Normality 
was tested with Shapiro-Wilk test and homoscedasticity was tested 
with Levene test. Preintake and postintake samples were compared 
by using both parametric (paired samples t-test) and nonparametric 
(Wilcoxon matched-pairs test) methods as appropriate. Adjusted 
p-value (p-adj) was calculated when an adjustment was necessary 
due to multiple comparisons (fdr test). P values ≤ 0.05 were 
considered statistically significant. All analyses were performed 
using GraphPad Prism version 6 software or R version 3.5.2.
REsULTs
Dasatinib Intake Inhibits the Migratory 
Capacity of T-Lymphocytes
To study the acute effects of dasatinib intake on lymphocyte 
migration, we obtained samples from 17 CML patients the day they 
began dasatinib treatment. PB samples were taken before the first 
drug intake (preintake) and 2 h later (postintake) from all patients. 
We first studied the acute effects of the first dasatinib intake on 
PBMC migration by performing a standard transwell assay using 
CCL19+CCL21 or CXCL12 as chemoattractants. Migrated cells 
were quantified and phenotyped for the main T lymphocyte 
subpopulations (CD4+ and CD8+ T-cells) and NK-cells.
Interestingly, the migratory index toward CCL19+CCL21 
was significantly reduced in both CD4+ and CD8+ T-cells 
(Figure 2A, upper panels). A similar tendency was found when 
the percentage of migration was analyzed, although differences 
did not reach significance (p = 0.097 for both CD4+ and CD8+ 
T-cells) (Figure 2A, lower panels).
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Conversely, the migration of NK-cells toward CCL19+CCL21 
was not affected by dasatinib intake. Furthermore, there was no 
significant effect on the migration of CD4+ T-cells, CD8+ T-cells, 
and NK-cells toward CXCL12 in postintake samples (Figure 2A).
Next, we aimed to analyze whether the inhibition observed 
in Figure 2A was due to a direct effect of dasatinib on the 
migratory capacity of lymphocytes. To this end, we performed 
migration experiments with PBMC from healthy donors (n = 11) 
pretreated in vitro with dasatinib for 1 h. This experiment 
revealed that dasatinib inhibited spontaneous T-cell migration, 
whereas chemotaxis toward CCL19, CCL21, and CXCL12 was 
not significantly affected (Figure 2B).
The First Dasatinib Intake Influences 
CCR7 Expression on T-Lymphocytes
In view of the previous results, an alternative explanation for the 
findings shown in Figure 2 could be the presence of a higher 
FIgURE 1 | Gating strategy to identify differentiation stages of T-cells. Lymphocytes were selected with a SSC/CD45 gate. Then, CD4+ and CD8+ T-cells were identified 
as CD3+CD8- or CD3+CD8+ lymphocytes, respectively (upper left). CCR7 expression on CD4+ and CD8+ T-cells is shown in a histogram (upper right). Finally, T-cell 
maturation stages were defined based on the differential expression of CCR7, CD45RA, and CD45RO on CD8+ (lower left) or CD4+ T-cells (lower right). TN = naïve 
T-cells (CD45RA+CCR7+); TCM = central memory T-cells (CD45RO+CCR7+); TEM = effector memory T-cells; TEMRA = CD45RA+ effector memory (CD45RA+CCR7-).
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proportion of CCR7 negative T-cells in the PB of the patients 
immediately after dasatinib intake. To confirm this hypothesis, 
we determined the percentage of CCR7+ and CXCR4+ cells in 
both CD4+ and CD8+ T-cell subsets and in NK-cells, both in 
preintake and postintake samples after the first dasatinib dose. This 
analysis first revealed that the percentage of expression of these 
chemokine receptors was very heterogeneous among patients 
before the first dasatinib intake (Figure 3A). This variability was 
already observed in CML patients at diagnosis (data not shown). 
After dasatinib intake, the percentage of CCR7+ cells in both 
CD4+ and CD8+ T lymphocytes was significantly lower (Figure 
3A, upper panels), whereas no significant changes were observed 
for CXCR4 in both CD4+ and CD8+ T-cells (Figure 3A, lower 
panels). Furthermore, no significant differences were observed in 
NK-cells (data not shown).
Dasatinib Favors the Accumulation of 
Effector T-Cells and Memory B-Cells in 
Peripheral Blood
CCR7 expression in combination with other molecules defines 
T-cell maturation stages. After the observation that dasatinib 
intake significantly decreased the proportion of CCR7+ T-cells, 
we performed a more detailed phenotypic analysis of lymphocyte 
subsets according to the expression of CCR7, CD45RA, and 
CD45RO. We observed an important redistribution of the 
FIgURE 2 | Dasatinib intake reduces CD4+ and CD8+ T-cell migration toward CCL19 and CCL21. (A) Blood samples were collected before (pre) and 2 h after 
(post) the first dasatinib intake in DASAPOST patients. Peripheral blood mononuclear cells (PBMCs) migration was studied by transwell assays, and compared 
between paired preintake (gray bars) and postintake (black bars) samples from DASAPOST patients (n = 12). The proportion of migrated cells in different cell 
populations is shown as migratory index (upper panels) and percentage of input (lower panels). (B) Migration transwell experiments with healthy donor PBMCs 
(n = 11) preincubated for 1 h (black bars) or not (gray bars) with dasatinib in vitro. Data are represented as means + SEM. Statistically significant p-adj values are 
shown on the graphs. ns, not significant.
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FIgURE 3 | (A) The first dasatinib intake changes the proportion of CCR7 positive T-cells. Percentages of CCR7+ and CXCR4+ lymphocytes in CD4+ and CD8+ 
T lymphocytes are compared between paired samples collected before (PRE) and 2 h after (POST) the first dasatinib intake from DASAPOST patients (CCR7, 
n = 17;CXCR4, n = 13). Data are represented as dot plots with lines connecting samples corresponding to the same patient. (B) T- and B-cell subsets redistribute 
differently in response to dasatinib therapy. Percentages of naïve (CCR7+CD45RA+)(TN), CD45RA+ effector memory (CCR7-CD45RA+)(TEMRA) and central memory 
(CCR7+CD45RO+)(TCM) CD4+ and CD8+ T-cells in total CD4+ and CD8+ T-cells (upper panels) and total lymphocytes (middle panels) are compared between paired 
preintake and postintake samples collected before (gray bars) and 2 h after (black bars) the first dasatinib intake from DASAPOST patients (n = 12). Percentages 
of memory B-cells in total B-cells and total lymphocytes in the same cohort of patients are shown (lower panels). Data in (B) are represented as mean + SEM. 
Statistically significant p-adj values are shown on the graphs. ns, not significant.
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different subsets within both CD4+ and CD8+ T-cells. In 
particular, dasatinib clearly increased the proportion of terminal 
effector CCR7-CD45RA+ T cells (TEMRA) in both the CD4+ and 
CD8+ T-cell subsets whereas in total lymphocytes only CD8+ 
TEMRA changed (Figure 3B, upper and middle panels).
Conversely, the proportion of T-cell subsets expressing CCR7, 
which include central memory CCR7+CD45RO+ (TCM) and naïve 
CCR7+CD45RA+ (TN) T-cells, significantly diminished: CD8+ 
TCM in both total CD8+ T-cells and total lymphocytes, CD4+ TCM 
in total lymphocytes, and TN in both CD4+ and CD8+ T-cells and 
total lymphocytes (Figure 3B, upper and middle panels).
Similarly, B-cell differentiation stages were identified by 
CD27 expression. We observed higher proportions of memory 
B-cells in total B-cells and total lymphocytes from the postintake 
samples (Figure 3B, lower panels).
Finally, we investigated whether these findings occurred after 
every drug intake. To this end, preintake and postintake samples 
from the same patients after 3 and 6 months of treatment and from 
patients from another cohort treated for more than 3 months with 
dasatinib, were also analyzed. Similar as to the first drug intake, 
chemotaxis to CCL19 and CCL21 significantly diminished 
in the postintake samples of patients previously treated with 
dasatinib: percentage of input 17% in the preintake sample vs. 
10% in the postintake sample (p = 0.0215). Furthermore, we 
could also confirm a redistribution of maturation stages and 
an accumulation of CD4+ and CD8+ TEMRA lymphocytes in PB 
(data not shown).
A Minority of Patients Do Not show 
Increased Absolute Lymphocyte Counts 
After Dasatinib Intake
The composition of the main lymphoid subsets also changed 
from the first intake, with a significant increase of absolute counts 
of B-cells, NK-cells, and T-cells (CD4+ and CD8+) 2 h after the 
intake (Figure 4A, left panel). Furthermore, the proportion of total 
T-cells and the CD4+ T-cells subset in total lymphocytes decreased 
in the postintake samples, whereas the proportions of CD8+ 
T-cells, B-cells, and NK-cells increased (Figure 4A, right panel).
Accordingly, absolute lymphocyte counts in blood increased 
significantly after the first dasatinib intake in most patients. 
However, we observed that 3 out of 17 CML patients did not 
have changes in absolute lymphocyte counts in the postintake 
samples. Therefore, we next divided the patients into "mobilizers" 
(n = 14) and "non mobilizers" (n = 3) (Figure 4B).
The mobilizers had, in addition to increased absolute counts 
of all lymphocyte subsets in postintake samples (Figure 4C, 
left panel), also increased percentage of total lymphocytes, 
as well as NK-cells and B-cells (Figure 4C, right panel). 
Conversely, a significant reduction of the proportion of CD3+ 
T-cells was observed in the postintake samples. Furthermore, 
the proportion of CD4+ T-cells in total T-cells significantly 
decreased whereas CD8+ T-cells increased. As expected, 
no differences in the proportion or absolute numbers of the 
different populations were observed in those three patients who 
did not have changes in lymphocyte counts between preintake 
and postintake samples (Figure 4C).
We next analyzed CCR7 expression in these two groups of 
patients and found that mobilizers had less CCR7+CD4+ T-cells 
than non mobilizers (Figure 4D). A similar tendency was found 
for CCR7+CD8+ T-cells, although the difference did not reach 
significance (p = 0.098).
These two groups of patients were compared in terms of the 
migratory capacity of T lymphocytes, since CCR7 expression on 
those cells tended to be different between the two groups. Both 
CD4+ and CD8+ T-cells showed lower migratory index toward 
CCL19+CCL21 in mobilizers (Figure 4E), whereas the migratory 
index toward CXCL12 was not significantly different between 
preintake and postintake samples from mobilizers (Figure 4E). 
Interestingly, no differences in CD4+ or CD8+ T-cell migration 
to any of the chemokines tested were observed in non mobilizers 
patients after dasatinib intake (Figure 4E).
DIsCUssION AND CONCLUsION
In addition to having potent effects on malignant cells, TKI also 
target kinases in normal cells, a process that is now known to 
have consequences in the immune system (Ilander et al., 2014). 
In this context, dasatinib, a second-generation broad-spectrum 
TKI, has many unique effects on the immune system such as a 
well-described rapid, dose-dependent, and substantial increment 
of lymphocyte numbers in the PB 1–2 h after an oral intake 
(Mustjoki et al., 2013). Nevertheless, neither the molecular 
mechanisms underlying this redistribution of lymphoid cells nor 
its immunological effects have been completely characterized. 
Other groups have claimed many different reasons to explain 
the lymphocytosis occurring during dasatinib therapy including 
viral reactivations and genetic mechanisms (Ilander et al., 2014; 
Paydas, 2014; Schiffer et al., 2016). However, to our knowledge, 
this is the first report associating the effects of dasatinib on T-cell 
migration in CML patients with lymphocytosis. Interestingly, the 
reduction of the migratory capacity of lymphocytes in response 
to CCR7 ligands in the post samples of patients is associated 
with an accumulation of CCR7 negative effector T lymphocytes 
into PB but not with direct effects of dasatinib on the migration 
toward CCL19 or CCL21, as we could observe in the in vitro 
experiments. Conversely, we found a significant reduction of 
lymphocyte spontaneous migration.
In order to confirm whether all these changes underlie the acute 
lymphocytosis caused by dasatinib, we separately analyzed three 
non mobilizers patients who did not have changes in the absolute 
lymphocyte count in the postintake samples and compared them 
with the mobilizer group of patients, which included most subjects 
of this study. Interestingly, these non mobilizers did not undergo 
any of the changes described here, including the redistribution of 
chemokine receptor expression or the change in the percentage of 
migration. A limitation of these results is the low number of non 
mobilizers. The differences are clear and our data are potentially 
interesting. However, to confirm these results, further studies with 
a higher number of patients would be required.
Our results therefore suggest that dasatinib-mediated 
lymphocytosis is partly due to a redistribution and accumulation 
of terminally differentiated CCR7 negative lymphocytes, both 
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CD4+ and CD8+ T-cells, as well as memory B-cells, in the 
bloodstream. Moreover, we favor the hypothesis that dasatinib 
recruits lymphocytes from SLO. Alternatively, this TKI may 
affect the capacity of terminally differentiated lymphocytes of 
exiting to the peripheral tissues, causing a lymphocyte blockage 
on the bloodstream translated into higher absolute lymphocyte 
counts. The inhibition of spontaneous migration in the in vitro 
experiments supports this last possibility in a scenario where CCR7 
positive cells would eventually leave the bloodstream following a 
chemotactic gradient whereas CCR7 negative lymphocytes would 
remain temporally "blocked" in PB due to yet undefined effects 
of dasatinib on motility, adhesion and/or deformability of CCR7 
negative lymphocytes.
Still an alternative or additional in vivo effect of dasatinib could 
be the inhibition of chemokine signals required for access of 
lymphocytes to tissues from the bloodstream, which would lead 
FIgURE 4 | Non mobilizers do not show changes in lymphocyte subsets, chemokine receptor expression and migratory capacity. (A) Absolute counts (left panel) and 
percentages (right panel) of T-, CD4-, CD8-, B- and NK-cells in total lymphocytes are compared between paired preintake and postintake samples collected before 
(gray bars) and 2 h after (black bars) the first dasatinib intake from DASAPOST patients (n = 17). (B) Patients from DASAPOST study were classified as mobilizers (n 
= 14) or non mobilizers (n = 3) depending on whether their absolute lymphocyte counts increased after the first dasatinib intake or not. (C) Absolute counts (left panel) 
and proportions (right panel) of total lymphocytes, T-cells, NK-cells, B-cells, CD4+ and CD8+ T-cells are compared between paired preintake and postintake samples 
from mobilizers (n = 14) and non mobilizers (n = 3). (D) Expression of CCR7 on CD4+ and CD8+ T-cells is compared between paired preintake and postintake 
samples from mobilizers (n = 9) and non mobilizers (n = 3). (E) Migration of CD4+ and CD8+ T-cells toward CCL19+21 or CXCL12 is compared between paired 
preintake and postintake samples from mobilizers (n = 9) and nonmobilizers (n = 3). Data are represented as medians+SEM. Statistically significant p-adj values are 
shown on the graphs. ns: not significant. Red bars, mobilizers; Blue bars: non mobilizers; light colors: preintake samples; dark colors: postintake samples
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to a transient accumulation of those lymphocytes and the typical 
lymphocytosis mediated by this TKI. In addition, dasatinib 
might block the intimate molecular connection between antigen 
receptor activation, both in B- and T-cells, and regulation of 
cell adhesion to other immune cells or to stromal cells through 
molecules including integrins and chemokine receptors 
(Carrasco and Batista, 2006; de Gorter et al., 2007; Arana et al., 
2008). This is quite intuitive since the immune synapse requires 
a temporary but stable interaction which is guaranteed by 
the adhesive connections between the cells involved and the 
surrounding microenvironment (Martín-Cófreces et al., 2018). 
In this regard, dasatinib inhibits kinases that are essential in both 
the B-cell receptor and T-cell receptor signalosomes like LYN, 
SYK, and BTK, and LCK, ITK, and ZAP-70, respectively (Berg 
et al., 2005; Chakraborty and Weiss, 2014; Seda and Mraz, 2015). 
Moreover, it is important to note that some of these signaling 
modules, including LCK and ZAP-70 are shared by chemokine 
receptors and the T-cell receptor and that some of the dasatinib 
targets, e.g., LYN or ITK phosphorylate actin-regulatory proteins 
like the hematopoietic linage cell-specific protein 1 (HS1). HS1 
plays a crucial role as an actin-regulatory protein and, therefore, 
in lymphocyte cytoarchitecture (Carrizosa et al., 2009). It is likely 
that the inhibition of all these pathways by dasatinib results in 
detachment and egress of lymphocytes from the SLO into PB.
This explanation has already been suggested for the mobilization 
of chronic lymphocytic leukemia or mantle lymphoma cells 
that occurs with B-cell receptor inhibitors like ibrutinib and 
fostamatinib (Buchner et al., 2010; de Rooij et al., 2012; McCaig 
et al., 2012; Chang et al., 2013; Purroy et al., 2017). In addition to 
these effects, dasatinib also inhibits the metastatic dissemination 
of solid tumors, an effect which seems to be mediated mainly 
through the inhibition of SFK (Montero et al., 2011).
Finally, we have recently demonstrated that dasatinib 
disrupts the homotypic interaction of endothelial cells through 
phosphorylation of the myosin light chain which, in turn, is 
probably dependent on the inhibition of SFK (Kreutzman et al., 
2017). This effect is reversible but the temporary loss of integrity 
of the endothelial surface where lymphocytes roll could interfere 
with their extravasation and explain, at least in part, the temporal 
accumulation of lymphocytes in the bloodstream.
As we have discussed above, dasatinib could be affecting 
different signal transduction pathways. At this stage it is unclear 
which molecular target/s are responsible for the effects of 
dasatinib described here. However, the identification of these 
targets is beyond the scope of our study.
Previous reports suggested that dasatinib induces a preferential 
mobilization of cytotoxic lymphocytes (Mustjoki et al., 2009; Nagata 
et al., 2010; Kreutzman et al., 2011; Mustjoki et al., 2013). Our results 
extend those observations and further demonstrate that effector 
CD4+ T-cells and memory B lymphocytes accumulate after dasatinib 
intake. These findings suggest that dasatinib is somehow affecting 
effector/memory lymphocytes independently of their linage. This 
connects with the interesting field of the different contractile, motile, 
adhesive, and migratory properties of lymphocytes depending on 
their maturation stage and/or homing patterns (Jacobelli et al., 2013; 
Mueller et al., 2013; Martín-Cófreces et al., 2018).
From a clinical perspective, the positive association between 
lymphocytosis and clinical response (Lee et al., 2011; Paydas, 
2014; Schiffer et al., 2016) would be justified not only by the 
mobilization and accumulation of cytotoxic lymphocytes but 
also by effector CD4+ T-cells and memory B lymphocytes that 
we have demonstrated here. It is important to highlight that this 
rapid mobilization of effector lymphocytes may have prognostic 
significance and occurs in the majority of patients, whereas a 
maintained lymphocytosis (defined as 3.6x109/L on at least two 
consecutive occasions after at least four weeks of treatment) occurs 
in a moderate percentage of patients treated with dasatinib (Lee 
et al., 2011; Mustjoki et al., 2013; Schiffer et al., 2016). In addition, 
we have shown for the first time that this rapid mobilization can 
be already seen the day the patients begin the treatment and it is 
likely to occur daily, as indicated by the results obtained in the 
same patient on the day the treatment begins and several months 
later. A chronic daily mobilization of effector CD4+ T-helper, 
cytotoxic CD8+ T-cells, and memory B lymphocytes into tissues 
infiltrated by the CML, such as PB and bone marrow, may account 
for the beneficial immunomodulatory effects of dasatinib.
One possible downside of this effect is that lymphocytosis 
may be associated with both beneficial effects and toxicity of 
dasatinib. Thus, the incidence of pleural effusion seems to be 
higher in patients who develop lymphocytosis, although it is 
only statistically significant in patients with advanced disease 
(Paydas, 2014; Schiffer et al., 2016; Hughes et al., 2019). A possible 
explanation to this association is that the extent of disruption of 
the endothelial cell monolayer (or other stromal cells of the SLO) 
is related to the magnitude of detachment and egress of effector 
lymphocytes; either because detachment is a consequence of the 
disassembly of endothelial cell-cell contacts, or because both 
effects are caused by the action of the drug on the same target. 
The increase in permeability would therefore be associated with 
a greater number of effector lymphocytes in peripheral blood, and 
both circumstances would favor a pleural effusion with effector 
lymphocytes, which may explain the exudative nature of the 
pleural effusion. It should be mentioned that in the largest study 
of patients receiving dasatinib therapy, advanced age and dose 
and longevity of treatment were found to be the only risk factors 
associated to pleural effusion (Hughes et al., 2019). In that sense, 
the prevalence of effusion with the current 100-mg QD scheme 
has been considerably reduced with respect to previous schedules, 
while the mobilization that we have described here seems to occur 
in the majority of patients with that same scheme. In addition, 
the lymphocyte mobilization induced by dasatinib seems to be 
controllable by drug dose (Mustjoki et al., 2013) and recent sub 
analyses of DASISION trial showed that dose reductions for adverse 
effects did not affect efficacy. This fact would offer us a therapeutic 
window to avoid toxic effects on the vascular endothelium but to 
take clinical advantage of the immediate mobilization of circulating 
effector and memory cells from all lymphoid subsets.
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